JK
Therapeutic Areas
Onco3R Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SIK | Autoimmune diseases | Phase 1 |
| FGFR3 | Bladder cancer | Phase 1/2 |
| SMARCA2 | Lung cancer | Preclinical |
| P53 | Solid tumors | Preclinical |
| Undisclosed | Immuno-oncology | Preclinical |
Leadership Team at Onco3R Therapeutics
PR
Pierre Raboisson
Chief Executive Officer
FG
François Gonzalvez
Chief Scientific Officer
GP
Guy Peeters
Chief Financial Officer
PP
Pieter Peeters
Chief Technology & Operations Officer
SV
Sandrine Vendeville
VP, Head of Medicinal Chemistry
JG
John-Paul Gallivan
SVP, Head of Development
FK
Fabrice Kolb
VP, Head of Immunology
LB
Lawrence Blatt
Chairman of the Board